

Publication List Dominique Laurent Braun (15.04.2021)

A) Original articles in peer reviewed journals

1. Raffenberg M, Engel T, Schoepf IC, Kootstra NA, Reiss P, **Braun DL**, Thorball CW, Fellay J, Kouyos RD, Ledergerber B, Gunthard HF, Tarr PE, Zurich Primary HIVIS, the Swiss HIVCS. *Impact of Delaying Antiretroviral Treatment during Primary HIV Infection on Telomere Length*. J Infect Dis 2021. (**Impact Factor 5.1**)
2. Courlet P, Barbioux C, Sculier D, Wandeler G, Stoeckle M, Bernasconi E, **Braun DL**, Vernazza P, Cavassini M, Marinosci A, Smit M, Gunthard HF, Schmid P, Limacher A, Guidi M, Alves Saldanha S, Decosterd LA, Calmy A. *Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trial*. Br J Clin Pharmacol 2021. (**Impact Factor 3.9**)
3. Kok YL, Vongrad V, Chaudron SE, Shilaih M, Leemann C, Neumann K, Kusejko K, Di Giallonardo F, Kuster H, **Braun DL**, Kouyos RD, Gunthard HF, Metzner KJ. *HIV-1 integration sites in CD4+ T-cells during primary, chronic, and late presentation of HIV-1 infection*. JCI Insight 2021. (**Impact Factor 6.2**)
4. Huber M, Schreiber PW, Scheier T, Audige A, Buonomano R, Rudiger A, **Braun DL**, Eich G, Keller DI, Hasse B, Boni J, Berger C, Gunthard HF, Manrique A, Trkola A. *High Efficacy of Saliva in Detecting SARS-CoV-2 by RT-PCR in Adults and Children*. Microorganisms 2021. (**Impact Factor 4.1**)
5. Kunzler-Heule P, Fierz K, Schmidt AJ, Rasi M, Bogdanovic J, Kocher A, Engberg S, Battegay M, Nostlinger C, Lehner A, Kouyos R, Schmid P, **Braun DL**, Fehr J, Nicca D. *Response to a sexual risk reduction intervention provided in combination with hepatitis C treatment by HIV/HCV co-infected men who have sex with men: a reflexive thematic analysis*. BMC Infect Dis 2021. (**Impact Factor 2.9**)
6. Rindler AE, Kuster H, Neumann K, Leemann C, **Braun DL**, Metzner KJ, Gunthard HF. *A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells*. Viruses 2021. (**Impact Factor 3.8**)
7. Hovaguimian F, Gunthard HF, Hauser C, Conen A, Bernasconi E, Calmy A, Cavassini M, Seneghini M, Marzel A, Heinrich H, Scherrer A, Riou J, Spoerri A, Schmidlin K, Balakrishna S, **Braun DL**, Rampini SK, Fehr JS, Kouyos RD, Swiss HIVCS. *Data linkage to evaluate the long-term risk of HIV infection in individuals seeking post-exposure prophylaxis*. Nature Communications 2021. (**Impact Factor 12.1**)
8. Neesgaard B, Mocroft A, Zangerle R, Wit F, Lampe F, Gunthard HF, Necsoi C, Law M, Mussini C, Castagna A, Monforte AD, Pradier C, Chkhartsvilli N, Reyes-Uruena J, Vehreschild JJ, Wasmuth JC, Sonnerborg A, Stephan C, Greenberg L, Llibre JM, Volny-Anne A, Peters L, Pelchen-Matthews A, Vannappagari V, Gallant J, Rieger A, Youle M, **Braun DL**, De Wit S, Petoumenos K, Borghi V, Spagnuolo V, Tsertsvadze T, Lundgren J, Ryom L, group Rs. *Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium*. PLoS One 2020. (**Impact Factor 2.7**)
9. Livio F, Deutschmann E, Moffa G, Rustemi F, Stader F, Elzi L, **Braun DL**, Calmy A, Hachfeld A, Cavassini M, Tarr PE, Wissel K, Battegay M, Marzolini C, and the SHCS. *Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequity*. Journal of Antimicrobial Chemotherapy. 2020. (**Impact Factor 5.2**)
10. Carlisle L, Turk T, Metzner KJ, Shah C, Böni J, Huber M, **Braun DL**, Fehr J, Salazar-Vizcaya L, Rauch A, Nguyen A, Cavassini M, Battegay M, Vernazza P, Bernasconi E, Günthard H, Kouyos R. *HCV genetic diversity can be used to infer infection recency and time since infection*. Viruses, 2020; in press (**Impact Factor 3.8**)
11. Sculier D, Wandeler G, Yerly S, Marinosci A, Stoeckle M, Bernasconi E, **Braun DL**, Vernazza P, Cavassini M, Buzzi M, Metzner M, Decosterd L, Günthard H, Schmid P, Limacher A, Egger M, and Calmy A. *Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-*

week results of the factorial, randomized, non-inferiority SIMPL-HIV trial. PLoS Medicine 2020, in press (**Impact Factor 9.3**)

12. **Braun DL**, Hampel B, Hampel B, Grube C, Nguyen H, Kuenzler-Heule P, Shah C, Salazar-Vizcaya L, Conen A, Flepp M, Stockle M, Beguelin C, Schmid P, Delaloye J, Rougemont M, Bernasconi E, Rauch A, Gunthard HF, Boni J, Kouyos R, Fehr JS, Swiss HIVCS. *A treatment as prevention trial to eliminate hepatitis C among men who have sex with men living with HIV in the Swiss HIV Cohort Study*. Clin Infect Dis 2020, in press. (**Impact Factor 9.1**)
13. Deutschmann E, Bucher H, Jaeckel S, Gibbons S, McAllister K, Scherrer A, **Braun DL**, Cavassini M, Hachfeld A, Calmy A, Battegay M, Cipriani M, Elzi L, Young J, Lopez-Centeno B, Berenguer J, Khoo S, Moffa G, Marzolini C, and the Swiss HIV Cohort Study. *Prevalence of potential drug-drug interactions in patients of the Swiss HIV Cohort Study in the era of HIV integrase inhibitors*. Clin Infect Dis 2020, in press. (**Impact Factor 9.1**)
14. Roth JA, Franzeck FC, Balakrishna S, Lautenschlager S, Thurnheer MC, Trelu LT, Cavassini M, Vernazza P, Bernasconi E, **Braun DL**, Kouyos RD, Battegay M, Swiss HIVCS. *Repeated Syphilis Episodes in HIV-Infected Men Who Have Sex With Men: A Multicenter Prospective Cohort Study on Risk Factors and the Potential Role of Syphilis Immunity*. Open forum infectious diseases 2020 (**Impact Factor 3.4**)
15. Gryaznov D, Chammartin F, Stoeckle M, Anagnostopoulos A, **Braun DL**, Furrer H, Boillat-Blanco N, Bernasconi E, Schmid P, Nordmann A, Bucher HC. *Smartphone app and carbon monoxide self-monitoring support for smoking cessation: A randomised controlled trial nested into the Swiss HIV Cohort Study*. J Acquir Immune Defic Syndr 2020.
16. Hampel B ‡, Kusejko K‡, Kouyos D, Böni J, Flepp M, Stöckle M, Conen A, Béguelin C, Künzler-Heule P, Nicca D, Schmidt A, Nguyen H, Delaloye D, Rougemont M, Bernasconi E, Rauch A, Günthard H, **Braun DL**‡, Fehr J‡. *Chemsex drugs on the rise – a longitudinal analysis of the Swiss HIV Cohort Study from 2007- 2017*. HIV Medicine 2019. ‡ contributed equally (**Impact Factor 3.7**)
17. Kunzler-Heule P, Engberg S, Battegay M, Schmidt AJ, Fierz K, Nguyen H, Kocher A, Nostlinger C, Hampel B, Stockle M, Beguelin C, Delaloye J, Schmid P, Flepp M, Rougement M, **Braun DL**, Fehr J, Nicca D, Swiss HIVCS. *Screening HIV-positive men who have sex with men for hepatitis C re-infection risk: is a single question on condom-use enough? A sensitivity analysis*. BMC Infect Dis 2019;19:821. (**Impact Factor 2.5**)
18. Barcelo C, Aouri M, Courlet P, Guidi M, **Braun DL**, Gunthard HF, Piso RJ, Cavassini M, Buclin T, Decosterd LA, Csajka C, Swiss HIVCS. *Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting*. J Antimicrob Chemother 2019;74:2690-2697. (**Impact Factor 5.2**)
19. Kusejko K, Salazar-Vizcaya L, **Braun DL**, Tarr PE, Bernasconi E, Doco-Lecompte T, Cavassini M, Schmid P, Du Pasquier R, Hauser C, Gunthard HF, Kouyos RD, Swiss HIVCS. *Self-reported neurocognitive impairment in people living with HIV: Characterizing clusters of patients with similar changes in self-reported neurocognitive impairment 2013-2017 in the Swiss HIV Cohort Study*. Clin Infect Dis 2019. (**Impact Factor 9.1**)
20. Kufner V, Plate A, Schmutz S, **Braun DL**, Gunthard HF, Capaul R, Zbinden A, Mueller NJ, Trkola A, Huber M. *Two Years of Viral Metagenomics in a Tertiary Diagnostics Unit: Evaluation of the First 105 Cases*. Genes (Basel) 2019;10. (**Impact Factor 3.6**)
21. Liechti T, Kadelka C, **Braun DL**, Kuster H, Boni J, Robbiani M, Gunthard HF, Trkola A. *Widespread B cell perturbations in HIV-1 infection afflict naïve and marginal zone B cells*. J Exp Med 2019;216:2071-2090. (**Impact Factor 10.9**)
22. Salazar-Vizcaya L, Kusejko K, Schmidt AJ, Carrillo-Montoya G, Nicca D, Wandeler G, **Braun DL**, Fehr J, Darling KEA, Bernasconi E, Schmid P, Gunthard HF, Kouyos RD, Rauch A. *Clusters of sexual behaviour in HIV-positive men who have sex with men reveal highly dissimilar time trends*. Clin Infect Dis 2019. (**Impact Factor 9.1**)
23. Kusejko K, Bachmann N, Chaudron SE, Nguyen H, **Braun DL**, Hampel B, Battegay M, Bernasconi E, Calmy A, Cavassini M, Hoffmann M, Boni J, Yerly S, Klimkait T, Perreau M, Rauch A, Gunthard HF, Kouyos RD, Swiss

HIVCS. *A Systematic Phylogenetic Approach to Study the Interaction of HIV-1 With Coinfections, Noncommunicable Diseases, and Opportunistic Diseases*. J Infect Dis 2019;220:244-253. **(Impact Factor 6.3)**

24. Carlisle LA, Turk T, Kusejko K, Metzner KJ, Leemann C, Schenkel CD, Bachmann N, Posada S, Beerenwinkel N, Boni J, Yerly S, Klimkait T, Perreau M, **Braun DL**, Rauch A, Calmy A, Cavassini M, Battegay M, Vernazza P, Bernasconi E, Günthard HF, Kouyos RD, Swiss HIVCS. *Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection*. J Infect Dis 2019;220:254-265. **(Impact Factor 6.3)**
25. Salazar-Vizcaya L, Kouyos RD, Metzner KJ, Caraballo Cortes K, Boni J, Shah C, Fehr J, **Braun DL**, Bernasconi E, Mbunkah HA, Hoffmann M, Labhardt N, Cavassini M, Rougemont M, Günthard HF, Keiser O, Rauch A, Swiss HIVCS. *Changing trends in international versus domestic HCV transmission in HIV-positive MSM: A perspective for the DAA scale-up era*. J Infect Dis 2019. **(Impact Factor 6.3)**
26. **Braun DL**, Turk T, Tschumi F, Grube C, Hampel B, Depmeier C, Schreiber P, Brugger S, Greiner M, Steffens D, de Torrenté-Bayard C, Courlet P, Neumann K, Kuster H, Flepp M, Bertisch B, Decosterd L, Böni J, Metzner K, Kouyos R, PhD; Günthard HF. *Non-inferiority of simplified dolutegravir monotherapy compared to continued combination antiretroviral therapy that was initiated during primary HIV infection: a randomized, controlled, multi-site, open-label, non-inferiority trial*. Clin Infect Dis 2019. **(Impact Factor 9.1)**
27. Kouyos RD, Rusert P, Kadelka C, Huber M, Marzel A, Ebner H, Schanz M, Liechi T, Friedrich N, **Braun DL**, Scherrer AU, Weber J, Uhr T, Baumann NS, Leemann C, Kuster H, Chave JP, Cavassini M, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Metzner KJ, Günthard HF, Trkola A; Swiss HIV Cohort Study. *Tracing HIV-1 strains that imprint broadly neutralizing antibody responses*. Nature 2018. **(Impact Factor 44.9)**
28. Salazar-Vizcaya L, Wandeler G, Fehr J, **Braun DL**, Cavassini M, Stoeckle M, Bernasconi E, Hoffmann M, Rougemont M, Beguelin C, Rauch A, Swiss HIVCS. *Impact of Direct-Acting Antivirals on the Burden of HCV Infection Among Persons Who Inject Drugs and Men Who Have Sex With Men in the Swiss HIV Cohort Study*. Open forum infectious diseases 2018. **(Impact Factor 3.2)**
29. **Braun DL**, Hampel B, Martin E, Kouyos R, Kusejko K, Grube C, Flepp M, Stockle M, Conen A, Beguelin C, Schmid P, Delaloye J, Rougemont M, Bernasconi E, Rauch A, Günthard HF, Boni J, Fehr JS, Swiss HIVCS. *High Number of Potential Transmitters Revealed in a Population-based Systematic Hepatitis C Virus RNA Screening Among Human Immunodeficiency Virus-infected Men Who Have Sex With Men*. Clin Infect Dis 2018. **(Impact Factor 9.1)**
30. **Braun DL**, Hampel B, Kouyos R, Nguyen H, Shah C, Flepp M, Stockle M, Conen A, Beguelin C, Kunzler-Heule P, Nicca D, Schmid P, Delaloye J, Rougemont M, Bernasconi E, Rauch A, Günthard HF, Boni J, Fehr JS, Swiss HIVCS. *High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men*. Clin Infect Dis 2018. **(Impact Factor 9.1)**
31. Kusejko K, Marzel A, Hampel B, Bachmann N, Nguyen H, Fehr J, **Braun DL**, Battegay M, Bernasconi E, Calmy A, Cavassini M, Hoffmann M, Boni J, Yerly S, Klimkait T, Perreau M, Rauch A, Günthard HF, Kouyos RD, Swiss HIVCS. *Quantifying the drivers of HIV transmission and prevention in men who have sex with men: a population model-based analysis in Switzerland*. HIV Med 2018. **(Impact Factor 3.4)**
32. Kadelka C, Liechi T, Ebner H, Schanz M, Rusert P, Friedrich N, Stiegeler E, **Braun DL**, Huber M, Scherrer AU, Weber J, Uhr T, Kuster H, Misselwitz B, Cavassini M, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Boni J, Kouyos RD, Günthard HF, Trkola A, Swiss HIVCS. *Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity*. J Exp Med 2018;215:1589-1608. [*shared last author] **(Impact Factor 11.9)**
33. Strouvelle VP*, **Braun DL***, Vongrad V, Scherrer AU, Kok YL, Kouyos RD, Stockle M, Rauch A, Darling K, Hoffmann M, Metzner KJ, Günthard HF, Zurich Primary HIVIS, the Swiss HIVCS. *No Effect of Pegylated Interferon-alpha on Total Hiv-1 DNA Load in HIV-1/HCV Coinfected Patients*. J Infect Dis 2018. [*shared first author] **(Impact Factor 6.3)**
34. Bachofner J, Valli PV, Bergamin I, Kroger A, Kunzler P, Baserga A, **Braun DL**, Seifert B, Moncsek A, Fehr J, Semela D, Magenta L, Mullhaupt B, Terziroli Beretta-Piccoli B, Mertens J, The Swiss Hepatitis CCS. *Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland*. Swiss Med Wkly 2018;148:w14560. **(Impact Factor 1.2)**

35. **Braun DL***, Marzel A*, Steffens D, Schreiber PW, Grube C, Scherrer AU, Kouyos RD, Gunthard HF, Swiss HIVCS. *High Rates of Subsequent Asymptomatic Sexually Transmitted Infections and Risky Sexual Behavior in Patients Initially Presenting With Primary Human Immunodeficiency Virus-1 Infection*. Clin Infect Dis 2018;66:735-42. [*shared first author] (**Impact Factor 9.1**)
36. Caniglia EC, Phillips A, Porter K, Sabin CA, Winston A, Logan R, Gill J, Vandenhende MA, Barger D, Lodi S, Moreno S, Arribas JR, Pacheco A, Cardoso SW, Chryso G, Gogos C, Abgrall S, Costagliola D, Meyer L, Seng R, van Sighem A, Reiss P, Muga R, Hoyos SP, **Braun DL**, Hauser C, Barrufet P, Leyes M, Tate J, Justice A, Hernan MA. *Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions*. J Acquir Immune Defic Syndr 2018;77:102-9. (**Impact Factor 3.9**)
37. Salazar-Vizcaya L, Kouyos RD, Fehr J, **Braun DL**, Estill J, Bernasconi E, Delaloye J, Stockle M, Schmid P, Rougemont M, Wandeler G, Gunthard HF, Keiser O, Rauch A, Swiss HIVCS. *On the potential of a short-term intensive intervention to interrupt HCV transmission in HIV-positive men who have sex with men: A mathematical modelling study*. J Viral Hepat 2018;25:10-8. (**Impact Factor 4.1**)
38. Hampel B, Kusejko K, **Braun DL**, Harrison-Quintana J, Kouyos R, Fehr J. *Assessing the need for a pre-exposure prophylaxis programme using the social media app Grindr(R)*. HIV Med 2017;18:772-6. (**Impact Factor 3.3**)
39. Ghisla V, Scherrer AU, Nicca D, **Braun DL***, Fehr JS*. *Incidence of hepatitis C in HIV positive and negative men who have sex with men 2000-2016: a systematic review and meta-analysis*. Infection 2017;45:309-21. [*shared last author] (**Impact Factor 2.3**)
40. del Amo J, Lodi S, Dray-Spira R, Wittkop L, Monge S, **Braun DL**, Vehreschild J, Teira R, Campbell C, d'Arminio Monforte A, Zangerle R, Ghosen J, Kourkounti S, Dabis F, Leport C, Meyer L, Termote M, Kirk O, Porter K, Spire B, Chene G, Egger M on behalf of COHERE in Euro-Coord. *Inequalities by educational level in response to combination antiretroviral treatment and survival in HIV-positive men and women in Europe*. AIDS. 2017;31(2):253-62. (**Impact Factor 4.4**)
41. Turk T, Bachmann N, Kadelka C, Boni J, Yerly S, Aubert V, Klimkait T, Battegay M, Bernasconi E, Calmy A, Cavassini M, Furrer H, Hoffmann M, Gunthard HF, Kouyos RD, Swiss HIVCS, Aubert V, Battegay M, Bernasconi E, Boni J, **Braun DL**, Bucher HC, Calmy A, Cavassini M, Ciuffi A, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, Gunthard HF, Haerry D, Hasse B, Hirsch HH, Hoffmann M, Hosli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos RD, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Marzolini C, Metzner KJ, Muller N, Nicca D, Pantaleo G, Paioni P, Rauch A, Rudin C, Scherrer AU, Schmid P, Speck R, Stockle M, Tarr P, Trkola A, Vernazza P, Wandeler G, Weber R, Yerly S. *Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis*. Elife 2017;6. (**Impact Factor 7.7**)
42. Shilaih M, Marzel A, **Braun DL**, Scherrer AU, Kovari H, Young J, Calmy A, Darling K, Battegay M, Hoffmann M, Bernasconi E, Thurnheer MC, Gunthard HF, Kouyos RD, and the Swiss HIVCS. *Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals*. Medicine (Baltimore). 2017;96(2):e5849. (**Impact Factor 2.1**)
43. Beguelin C, Moradpour D, Sahli R, Suter-Riniker F, Luthi A, Cavassini M, Gunthard HF, Battegay M, Bernasconi E, Schmid P, Calmy A, **Braun DL**, Furrer H, Rauch A, Wandeler G, Swiss HIVCS. *Hepatitis delta-associated mortality in HIV/HBV-coinfected patients*. J Hepatol. 2017;66(2):297-303. (**Impact Factor 11.3**)
44. Bachofner JA, Valli PV, Kroger A, Bergamin I, Kunzler P, Baserga A, **Braun DL**, Seifert B, Moncsek A, Fehr J, Semela D, Magenta L, Mullhaupt B, Terziroli Beretta-Piccoli B, Mertens JC. *Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index*. Liver Int. 2017;37(3):369-76. (**Impact Factor 4.5**)
45. Shilaih M, Marzel A, Scherrer AU, **Braun DL**, Kovari H, Rougemont M, Darling K, Battegay M, Hoffmann M, Bernasconi E, Hirzel C, Gunthard HF, Kouyos RD, Swiss HIVCSa, Swiss HIVCS. *Dually Active HIV/HBV Antiretrovirals as Protection Against Incident Hepatitis B Infections: Potential for Prophylaxis*. J Infect Dis. 2016;214(4):599-606. (**Impact Factor 6.3**)
46. Rusert P, Kouyos RD, Kadelka C, Ebner H, Schanz M, Huber M, **Braun DL**, Hoze N, Scherrer A, Magnus C, Weber J, Uhr T, Cippa V, Thorball CW, Kuster H, Cavassini M, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Boni J, Fellay J, Regoes RR, Gunthard HF, Trkola A, Swiss HIVCS. *Determinants of HIV-1 broadly neutralizing antibody induction*. Nat Med. 2016;22(11):1260-7. (**Impact Factor 30.4**)
47. Oberle CS, Joos B, Rusert P, Campbell NK, Beauparlant D, Kuster H, Weber J, Schenkel CD, Scherrer AU, Magnus C, Kouyos R, Rieder P, Niederost B, **Braun DL**, Pavlovic J, Boni J, Yerly S, Klimkait T, Aubert V, Trkola A, Metzner

KJ, Gunthard HF, Swiss HIVCS. *Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs. Retrovirology.* 2016;13(1):62. **(Impact Factor 4.0)**

48. Marzel A, Shilaih M, Yang WL, Boni J, Yerly S, Klimkait T, Aubert V, **Braun DL**, Calmy A, Furrer H, Cavassini M, Battegay M, Vernazza PL, Bernasconi E, Gunthard HF, Kouyos RD, Swiss HIVCS. *HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study.* Clin Infect Dis. 2016;62(1):115-22. **(Impact Factor 8.2)**
49. Gjaerde LI, Shepherd L, Jablonowska E, Lazzarin A, Rougemont M, Darling K, Battegay M, **Braun DL**, Martel-Laferriere V, Lundgren JD, Rockstroh JK, Gill J, Rauch A, Mocroft A, Klein MB, Peters L. *Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study.* Clin Infect Dis. 2016;63(6):821-9. **(Impact Factor 8.2)**
50. **Braun DL**, Rauch A, Aouri M, Durisch N, Eberhard N, Anagnostopoulos A, Ledergerber B, Mullhaupt B, Metzner KJ, Decosterd L, Boni J, Weber R, Fehr J, Swiss HIVCS. *A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.* PLoS One. 2015;10(7):e0133028. **(Impact Factor 4.4)**
51. **Braun DL**, Kouyos RD, Balmer B, Grube C, Weber R, Gunthard HF. *Frequency and Spectrum of Unexpected Clinical Manifestations of Primary HIV-1 Infection.* Clin Infect Dis. 2015;61(6):1013-21. **(Impact Factor 8.2)**
52. Kouyos RD, Rauch A, **Braun DL**, Yang WL, Boni J, Yerly S, Klimkait T, Aubert V, Shah C, Kovari H, Calmy A, Cavassini M, Battegay M, Vernazza PL, Bernasconi E, Ledergerber B, Gunthard HF, Swiss HIVCS. *Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wide.* J Infect Dis. 2014;210(10):1555-61. **(Impact Factor 5.9)**
53. **Braun DL**, Rauch A, Durisch N, Eberhard N, Anagnostopoulos A, Ledergerber B, Metzner KJ, Boni J, Weber R, Fehr J. *Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients.* HIV Med. 2014;15(10):625-30. **(Impact Factor 3.4)**
54. **Braun DL**, Kouyos R, Oberle C, Grube C, Joos B, Fellay J, McLaren PJ, Kuster H, Gunthard HF. *A novel Acute Retroviral Syndrome Severity Score predicts the key surrogate markers for HIV-1 disease progression.* PLoS One. 2014;9(12):e114111. **(Impact Factor 4.4)**
55. Mocroft A, Furrer HJ, Miro JM, Reiss P, Mussini C, Kirk O, Abgrall S, Ayayi S, Bartmeyer B, **Braun DL**, Castagna A, d'Arminio Monforte A, Gazzard B, Gutierrez F, Hurtado I, Jansen K, Meyer L, Munoz P, Obel N, Soler-Palacin P, Papadopoulos A, Raffi F, Ramos JT, Rockstroh JK, Salmon D, Torti C, Warszawski J, de Wit S, Zangerle R, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Lundgren JD, Opportunistic Infections Working Group on behalf of the Collaboration of Observational HIVRESiE. *The incidence of AIDS-defining illnesses at a current CD4 count \geq 200 cells/ μ L in the post-combination antiretroviral therapy era.* Clin Infect Dis. 2013;57(7):1038-47. **(Impact Factor 8.2)**
56. Rieder P, Joos B, Scherrer AU, Kuster H, **Braun DL**, Grube C, Niederost B, Leemann C, Gianella S, Metzner KJ, Boni J, Weber R, Gunthard HF. *Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection.* Clin Infect Dis. 2011;53(12):1271-9. **(Impact Factor 8.2)**
57. Metzner KJ, Leemann C, Di Giallonardo F, Grube C, Scherrer AU, **Braun DL**, Kuster H, Weber R, Gunthard HF. *Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection.* PLoS One. 2011;6(7):e21734. **(Impact Factor 4.4)**

B) Reviews / letters / editorials (peer reviewed)

1. Tschumi F, Brugger SD, **Braun DL**. [CME: Dyslipidemia and Cardiovascular Risk in HIV Infected Patients]. Praxis (Bern 1994) 2019;108:451-458
2. Hoenigl M, **Braun DL**, Kouyos R, Gunthard HF, Little SJ. *Evaluation of the Predictive Potential of the Short Acute Retroviral Syndrome Severity Score for HIV-1 Disease Progression in Individuals With Acute HIV Infection.* J Acquir Immune Defic Syndr. 2017;74(4):e114-e7. **(Impact Factor 3.8)**
3. **Braun DL**, Nemeth J, Gunthard HF. *Don't miss the primary HIV-infection.* Ther Umsch. 2014;71(8):469-74.

C) Case reports (peer reviewed)

1. **Braun DL**, Scheier T, Ledermann U, Flepp M, Metzner K, Böni J, Günthard H. *Emergence of resistance to Integrase Strand Transfer Inhibitors during dolutegravir containing triple-therapy in a treatment-experienced patient with pre-Existing M184V/I mutation*. *Viruses* 2020, 12, 1330. (**Impact Factor 3.76**)
2. **Braun DL**, Hasse BK, Stricker J, Fehr JS. *Prosthetic valve endocarditis caused by Propionibacterium species successfully treated with coadministered rifampin: report of two cases*. *BMJ Case Rep*. 2013;2013.
3. von Braun A*, **Braun DL***, Kamarachev J, Günthard HF. *New onset of kaposi sarcoma in a human immunodeficiency virus-1-infected homosexual man, despite early antiretroviral treatment, sustained viral suppression, and immune restoration*. *Open forum infectious diseases*. 2014;1(1):ofu005. [*shared first author]
4. **Braun DL**, Horovitz A, Berteau M, Jenni R, Günthard HF. *Aortic homograft endocarditis caused by Cardiobacterium hominis and complicated by agranulocytosis due to ceftriaxone*. *BMJ Case Rep*. 2010;2010.